Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release May 17 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Ephedrine Sulfate Injection. This injection is indicated for treating hypotension during anesthesia and will be manufactured at their facility in Jarod, India. The press release highlights that the drug had significant annual sales in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases